Results of Friday’s FDA Advisory Committee Meeting

September 20, 2021

Last Friday, the FDA’s key advisory committee convened for an 8-hour meeting to discuss and vote on boosters for those 16+ years of age. 84% of committee members voted “no” on boosters for the general population, citing safety concerns and a lack of data on the reduction of transmission after a third dose. In an unexpected turn of events, the FDA advisory committee created and voted on a second question, as to whether the known and potential benefits outweigh the known and potential risks of the Pfizer Covid booster – at least 6 months after the primary series – for use in those 65+ and those at high risk of severe COVID-19. Panelists voted “yes” unanimously. 

Since “high risk” can be broadly interpreted, many Americans who wish to be given a booster may be eligible. Additional doses for immunocompromised persons, including those with autoimmune disease who may not have developed sufficient antibodies after their primary vaccination series, are eligible for a COVID-19 booster dose. 

The FDA typically follows the committee’s recommendations, but it is not mandatory that they do so. The FDA will most likely issue a decision this week, possibly before the CDC’s ACIP meeting on Wednesday. The CDC will develop vaccine policy based on the recommendations of the CDC advisory committee.





Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.